Brief: Bellicum Pharma Announces Rivo-Cel Achieves Primary Endpoint In Pediatric Registrational Trial
08/07/2019 13:26
July 8 (Reuters) - Bellicum Pharmaceuticals Inc BLCM.O :
* BELLICUM PHARMACEUTICALS ANNOUNCES RIVO-CEL™ ACHIEVES
PRIMARY
ENDPOINT IN PEDIATRIC REGISTRATIONAL TRIAL
* BELLICUM PHARMACEUTICALS INC - BELLICUM IS ACTIVELY
SEEKING A
STRATEGIC PARTNER FOR RIVO-CEL IN ANTICIPATION OF A POTENTIAL
COMMERCIAL LAUNCH
Source text for Eikon: ID:nGNX51YcdB
Further company coverage: BLCM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview